Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Accurate protein modeling can help develop new treatments for prostate cancer and other diseases.

This study found that Medicare patients with benign prostatic hyperplasia had high adherence to 5-alpha reductase inhibitor therapy, which was associated with a reduced risk of needing surgical intervention.

This letter discusses the potential of green tea extract as a treatment for hirsutism but reports no clinical outcomes.

This review summarizes the bioactive compounds and pharmacological functions of Cynomorium songaricum Rupr., emphasizing its potential in developing health-related products, and notes that further research is needed.

This review article examines the current understanding of frontal fibrosing alopecia, noting its prevalence in different demographics and the roles of genetic and environmental factors in its pathogenesis, while highlighting that treatment approaches remain varied and lack standardization.

This literature review identified that phosphodiesterase 5 inhibitors, such as Tadalafil, are highly effective in improving lower urinary tract symptoms associated with benign prostatic hyperplasia, while the efficacy of saw palmetto remains inconsistent.

In this study, ELE was found to protect against oxidative stress-induced testosterone reduction in TM3 Leydig cells by increasing testosterone synthesis and decreasing its conversion.

This study suggests that type I 5-alpha reductase may also play a role in hair growth, with dutasteride potentially being more potent than finasteride in modulating key hair growth gene expressions.

Hidradenitis Suppurativa is a chronic skin condition best treated early with surgery for better outcomes and less recurrence.

This study found that dutasteride was more effective than finasteride in reducing total prostate volume and PSA levels and improving symptoms in patients with benign prostate hyperplasia.

This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.

This review highlights that 5 Alpha Reductase Inhibitors, used for treating conditions like benign prostatic hypertrophy, can cause side effects that sometimes persist after stopping the medication, urging physicians to consider these drugs as potential sources of new symptoms in patients.

In this study, researchers found that Ectoin, derived from halophilic bacteria, can mitigate stress-related skin damage by reducing cortisone's inhibitory effects on essential skin proteins and decreasing UVB-induced glucocorticoid activity, highlighting its potential as a preventative agent for stress-induced skin issues.

This review discusses treatments for androgenic alopecia, including minoxidil, finasteride, and hormonal therapies with antiandrogens, and reports no new clinical findings.

In this review, the authors highlight the involvement of the 5α-reductase enzyme family in androgen-dependent disorders, noting the discovery of a novel isoform, SRD5A3, which is overexpressed in cancers with poor prognosis.

This article discusses how 5-alpha-reductase inhibitors like finasteride and dutasteride are used to treat androgenetic alopecia, while highlighting the ongoing debate over their potential side effects, including sexual dysfunction and psychological issues.

This systematic review found that treatments for sickle cell disease-related priapism are clinically diverse, with etilefrine, pseudoephedrine/etilefrine-5 inhibitors, and finasteride appearing promising, but further research with robust study designs is needed to establish evidence-based practices.

In this study, the researchers found that glucocorticoid receptor activation may influence glucose metabolism, with preventive GR antagonist treatment reducing hyperglycemia and restoring glucose tolerance in a PCOS mouse model.

This animal study found that finasteride, a 5-alpha reductase type 2 inhibitor, decreased dihydrotestosterone levels and c-Fos protein activation in the rat brain, but these effects may diminish after discontinuing the drug.

This review discusses the potential of phytochemicals from plants as alternative treatments for prostate cancer, highlighting their possible benefits over current 5-alpha-Reductase inhibitors, but reports no new findings.

This review explores plant-derived phytochemicals, such as phytosterols, polyphenols, and fatty acids, for their potential use as alternative treatments for prostate cancer, emphasizing their effects on 5-alpha-Reductase enzyme isozymes. It reports no new clinical results.

This article updates a prior work on pharmacophore modeling and highlights the advances in 3D database searching technologies for drug design, without presenting new research findings.

This article reviews mechanisms by which herbal ingredients may stimulate or inhibit hair growth, and it reports no new clinical findings while suggesting potential for developing hair loss treatments.

This review discusses the involvement of type I interferons in skin autoimmune and inflammatory diseases but reports no new clinical results.

This review compiles existing data on frontal fibrosing alopecia and highlights the promise of 5-alpha reductase inhibitors as a treatment option, while noting the need for clarity on its cause and progression.

In this study, fraction No. 3 of Oryza sativa bran extract demonstrated high unsaturated fatty acid content and significant 5α-reductase inhibition, suggesting potential for developing anti-androgenic alopecia products.

This article reviews the effects of 5 alpha-reductase inhibitors for treating conditions like male pattern baldness and benign prostatic hyperplasia, noting significant DHT reduction but reports no new clinical results.

This study describes a case where stopping infliximab and using oral minocycline with topical treatments effectively resolved alopecia and scalp psoriasis in a woman with Crohn's disease.

This study found that compounds 21–23 and 25 exhibited strong 5α-reductase II inhibition in vitro and significantly reduced rat prostate weight, performing comparably to finasteride.

This study found that the phytosterols β-sitosterol, stigmasterol, and campesterol have low-to-negligible inhibitory activity against steroidal 5α-reductase type 2 compared to the synthetic inhibitor dutasteride, with β-sitosterol showing the highest activity among the tested phytosterols.